Home  »  Hot Stocks   »  Here’s Our Rant About Moleculin Biotech Inc....

Here’s Our Rant About Moleculin Biotech Inc. (MBRX)

Moleculin Biotech Inc. (NASDAQ:MBRX) went down by -6.62% from its latest closing price compared to the recent 1-year high of $2.33. The company’s stock price has collected 24.51% of gains in the last five trading sessions. The Wall Street Journal reported on 02/02/21 that GameStop, UPS, Silver: What to Watch When the Stock Market Opens Today

Is It Worth Investing in Moleculin Biotech Inc. (NASDAQ :MBRX) Right Now?

Plus, the 36-month beta value for MBRX is at 1.80. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Moleculin Biotech Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The average price from analysts is $8.67, which is $7.4 above the current price. MBRX currently public float of 27.96M and currently shorts hold a 0.18% ratio of that float. Today, the average trading volume of MBRX was 110.39K shares.

MBRX’s Market Performance

MBRX stocks went up by 24.51% for the week, with a monthly jump of 37.16% and a quarterly performance of -9.93%, while its annual performance rate touched -38.05%. The volatility ratio for the week stands at 12.55% while the volatility levels for the past 30 days are set at 7.99% for Moleculin Biotech Inc. The simple moving average for the period of the last 20 days is 27.59% for MBRX stocks with a simple moving average of -11.23% for the last 200 days.

Analysts’ Opinion of MBRX

Many brokerage firms have already submitted their reports for MBRX stocks, with Oppenheimer repeating the rating for MBRX by listing it as a “Outperform.” The predicted price for MBRX in the upcoming period, according to Oppenheimer is $14 based on the research report published on July 18th of the current year 2022.

MBRX Trading at 19.96% from the 50-Day Moving Average

After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.49% of loss for the given period.

Volatility was left at 7.99%, however, over the last 30 days, the volatility rate increased by 12.55%, as shares surge +36.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.56% lower at present.

During the last 5 trading sessions, MBRX rose by +24.51%, which changed the moving average for the period of 200-days by -16.45% in comparison to the 20-day moving average, which settled at $1.0124. In addition, Moleculin Biotech Inc. saw -31.72% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MBRX starting from KLEMP WALTER V, who purchase 22,500 shares at the price of $1.15 back on Nov 21. After this action, KLEMP WALTER V now owns 364,890 shares of Moleculin Biotech Inc., valued at $25,866 using the latest closing price.

KLEMP WALTER V, the CEO and President of Moleculin Biotech Inc., purchase 24,742 shares at $1.02 during a trade that took place back on Nov 17, which means that KLEMP WALTER V is holding 342,390 shares at $25,257 based on the most recent closing price.

Stock Fundamentals for MBRX

Equity return is now at value -36.30, with -33.30 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 20.02.